<DOC>
	<DOCNO>NCT02600923</DOCNO>
	<brief_summary>The purpose study provide access palbociclib Mexico select Latin American country become commercially available patient HR positive/HER2-negative ABC appropriate candidate letrozole therapy .</brief_summary>
	<brief_title>Palbociclib Plus Letrozole For Postmenopausal Women With HR ( + ) HER2 ( - ) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Adult woman proven diagnosis advanced adenocarcinoma breast ( locoregional recurrent metastatic disease ) . Women childbearing potential . ERpositive and/or Progesterone receptor ( PgR ) positive tumor base local laboratory result ( test per local practice ) . HER2negative breast cancer base local laboratory result ( test per local practice local guideline ) . Patients must appropriate candidate letrozole therapy . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Adequate bone marrow function . Adequate liver function Adequate renal function . Known hypersensitivity letrozole , excipients , palbociclib excipients . Current use food drug know potent inhibitor inducer CYP3A4 isoenzymes within 7 day prior study entry . Prior treatment CDK inhibitor . Previous participation palbociclib clinical study . Participation study involve investigational drug ( ) within 2 week prior study entry and/or study participation . QTc &gt; 480 msec ; history QT syndrome , Brugada syndrome know history QTc prolongation , Torsade de Pointes . High cardiovascular risk , include , limited recent myocardial infarction , severe/unstable angina severe cardiac dysrhythmias past 6 month prior enrollment . Diagnosis second invasive malignancy within last 3 year prior enrollment . Note : patient adequately treat basal cell squamous cell skin cancer , history intraepithelial neoplasia situ disease ( eg , carcinoma situ cervix melanoma situ ) may enter . Active uncontrolled symptomatic brain metastasis . Previously treat clinically stable , brain metastasis permit . Other severe acute chronic medical psychiatric condition . Patients investigational site staff member directly involved conduct study family member , site staff member otherwise supervised investigator , patient Pfizer employee directly involve conduct study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>palbociclib , ibrance , breast cancer</keyword>
</DOC>